Skip to main content

Advertisement

SpringerLink
Log in

Development and Validation of Stability Indicating RP-HPLC Method for the Determination of Process and Degradation-Related Impurities in Sugammadex Sodium Drug Substance

  • Original
  • Published:
Chromatographia Aims and scope Submit manuscript

Abstract

The aim of this study is to develop and validate a sensitive and specific stability-indicating reversed-phase high-performance liquid chromatographic (RP-HPLC) method for the quantitative determination of Sugammadex sodium together with its process and possible degradation impurities. The pKa value is 2.82. The chromatographic conditions have been optimized by the Hypersil Gold 250 mm X 4.6 mm, 3 µ RP-18 columns with gradient elution using a mobile phase composed of 0.1% phosphoric acid, acetonitrile, and methanol. The eluents were monitored at 205 nm with a flow rate of 1.0 mL/min with an injection volume of 20 µL. The optimized method produced symmetrical and sharp peaks with good separation between the process and degradation impurities. The forced degradation study was carried out under acid, base, oxidation, and thermal conditions to demonstrate the stability-indicating capability of the method. The method was validated as per the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) Q2 (R1) and showed excellent specificity, precision, linearity, accuracy, and robustness. The developed HPLC method was precise with a value of 0.25%. The relative standard deviation of accuracy represented by the recovery studies ranged between 89.5% and 104.6%. Linearity analyses indicated a correlation coefficient value of greater than 0.996 for Sugammadex and its known impurities. The LOD and LOQ values for Sugammadex ranged from 0.017% to 0.050%, and for its related impurities, they ranged from 0.015% to 0.055%. The stability of the analytical solution was evaluated and was stable for 75 h when stored at 5 °C. No chromatographic interference was observed during the degradation studies and also in the blank chromatogram.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Kovac AL (2009) Sugammadex: the first selective binding reversal agent for neuromuscular block. J Clin Anesth 21(6):444–453

    Article  CAS  Google Scholar 

  2. Rahe-Meyer N, Berger C, Wittmann M, Solomon C, Abels E, Rietbergen H, Reuter D (2015) Recovery from prolonged deep rocuronium-induced neuromuscular blockade. Anaesthesist 64(7):506–512

    Article  CAS  Google Scholar 

  3. Lemmens HJM, El-Orbany MI, Berry J, Morte JB, Martin G (2010) Reversal of profound vecuronium-induced neuromuscular block under sevoflurane anesthesia: sugammadex versus neostigmine. BMC Anesthesiol 10(1):1–10

    Article  Google Scholar 

  4. Khuenl-Brady KS, Wattwil M, Vanacker BF, Lora-Tamayo JI, Rietbergen H, Álvarez-Gómez JA (2010) Sugammadex provides faster reversal of vecuronium-induced neuromuscular blockade compared with neostigmine: a multicenter, randomized, controlled trial. Anesth Analg 110(1):64–73

    Article  Google Scholar 

  5. Jones RK, Caldwell JE, Brull SJ, Soto RG (2008) Reversal of profound rocuronium-induced blockade with sugammadex: a randomized comparison with neostigmine. J Am Soc Anesthesiol 109(5):816–824

    Article  CAS  Google Scholar 

  6. Geldner G, Niskanen M, Laurila P, Mizikov V, Hübler M, Beck G, Rietbergen H, Nicolayenko E (2012) A randomized controlled trial comparing sugammadex and neostigmine at different depths of neuromuscular blockade in patients undergoing laparoscopic surgery. Anaesthesia 67(9):991–998

    Article  CAS  Google Scholar 

  7. De Zwart MA, ten Bruggencate-Broeders J, Van Hal HJ, Megens RHJ, Frasa HWL (2011) Determination of sugammadex in human plasma, urine, and dialysate using a high-performance liquid chromatography/tandem mass spectrometry assay. J Chromatogr B 879(19):1573–1586

    Article  Google Scholar 

  8. Chakravarthy A, Sailaja BBV, Praveen Kumar A (2017) Method development and validation of ultraviolet-visible spectroscopic method for the estimation of assay of sugammadex sodium, apremilast, riociguat, and vorapaxar sulfate drugs in active pharmaceutical ingredient form. Asian J Pharm Clin Res 10(2):241–250

    Article  CAS  Google Scholar 

  9. Aluc K, Kaya G, Gokalp M (2021) A validated ultra –high-pressure liquid chromatography method for separation of sugammadex related substances and its detergents in drug products. Global J Pharm Pharmaceut Sci 8(3):2573–2250

    Google Scholar 

  10. Mashru R, Parekh H, Chokshi P (2020) Analytical Method Development and Validation for the Estimation of Sugammadex. J Drug Deliv Therapeut 10(1):52–59

    Article  Google Scholar 

  11. Gijsenbergh F, Ramael S, Houwing N, van Iersel T (2005) First human exposure of Org 25969, a novel agent to reverse the action of rocuronium bromide. J Am Soc Anesthesiol 103(4):695–703

    Article  CAS  Google Scholar 

  12. Nicholson WT, Sprung J, Jankowski CJ (2007) Sugammadex: a novel agent for the reversal of neuromuscular blockade. Pharmacother J Hum Pharmacol Drug Ther 27(8):1181–1188

    Article  CAS  Google Scholar 

  13. Bom A, Epemolu O, Hope F, Rutherford S, Thomson K (2007) Selective relaxant binding agents for reversal of neuromuscular blockade. Curr Opin Pharmacol 7(3):298–302

    Article  CAS  Google Scholar 

  14. Lemmens HJ, El-Orbany MI, Berry J, Morte JB, Martin G (2010) Reversal of profound vecuronium-induced neuromuscular block under sevoflurane anesthesia: sugammadex versus neostigmine. BMC Anesthesiol 10(1):1–10

    Article  Google Scholar 

  15. Welliver M (2006) New drug sugammadex: a selective relaxant binding agent. AANA J 74(5):357–363

    PubMed  Google Scholar 

  16. I.H.T. Guideline, Impurities in new drug substances Q3A (R2) (2006) In Proceedings of the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use, Geneva, Switzerland, 25

  17. I.H.T. Guideline (2005). Validation of analytical procedures: text and methodology, Q2 (R1), 1 ,1–15

  18. Merrill JC. (1987). HPLC for Pharmaceutical scientist.Am. Lab. 7481.

  19. Bliesner DM (2006) Validating Chromatographic Methods. John Wiley. 88–92

  20. A Guide to Validation in HPLC Based on the Work of G.M. Hearn Perkin Elmer. R.A. van Iterson Drenthe College Emmen Holland for www.standard base.com. Accessed April 05, 2013

  21. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (2005). “ICH Q2 (R1) Validation of Analytical Procedures: Text and Methodology,” vol. 1994, 17.

  22. FDA (2014) Guidance for Industry Analytical Procedures and Methods Validation for Drugs and Biologics

  23. Kavitapu DR, Maruthapillai A, Mahapatra S, Selvi JA (2021) New stability-indicating RP-HPLC method for the determination of Abiraterone acetate, its related substances and degradation products in bulk and dosage form. Mater Today Proc 34:469–478

    Article  CAS  Google Scholar 

  24. ICH Harmonised Tripartite Guideline Q1A (R2) (2003) Stability Testing of New Drug Substances and Products

  25. Sabir AM, Moloy M, Bhasin PS (2013) HPLC method development and validation: A review. Int Res J Pharm 4(4):39–46

    Article  Google Scholar 

  26. Ragham PK, Chandrasekhar KB (2016) Development and validation of a stability-indicating RP-HPL C-CAD method for gabapentin and its related impurities in presence of degradation products. J Pharm Biomed Anal 125:122–129

    Article  CAS  Google Scholar 

  27. Sahu PK, Ramisetti NR, Cecchi T, Swain S, Patro CS, Panda J (2018) An overview of experimental designs in HPLC method development and validation. J Pharm Biomed Anal 147:590–611

    Article  CAS  Google Scholar 

  28. Ngwa G (2010) Forced degradation as an integral part of HPLC stability-indicating method development. Drug Delivery Tech 10(5):56–59

    CAS  Google Scholar 

  29. I.S. Committee (1996) ICH Q2B validation of analytical procedures: methodology. European agency for the evaluation of medicinal products, International commission on harmonisation, London, (CPMP/ICH/281/95)

  30. I.S. Committee (1996) ICH Q2B validation of analytical procedures: methodology. European agency for the evaluation of medicinal products, International commission on harmonisation, London (CPMP/ICH/281/95)

  31. U. S. Pharmacopeia (2009). “USP-NF <1225> Validation of Compendial Methods,” USP 32-NF27

Download references

Funding

The author, Dr. K. Venkatachalam is extremely thankful for the financial help for the DST-SERB project of the Department of Science and Technology, India (Ref. No EEQ/2016/000559, Date: 06.02.2017).

Author information

Authors and Affiliations

  1. Department of Analytical Chemistry, University of Madras, Guindy Campus, Chennai, Tamil Nadu, 600025, India

    K. Samuel Barnabas, S. Prashanna Suvaitha & K. Venkatachalam

Authors
  1. K. Samuel Barnabas
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S. Prashanna Suvaitha
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. K. Venkatachalam
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to K. Venkatachalam.

Ethics declarations

Conflicts of interest

There are no conflicts of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Barnabas, K.S., Suvaitha, S.P. & Venkatachalam, K. Development and Validation of Stability Indicating RP-HPLC Method for the Determination of Process and Degradation-Related Impurities in Sugammadex Sodium Drug Substance. Chromatographia 85, 405–419 (2022). https://doi.org/10.1007/s10337-022-04146-y

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10337-022-04146-y

Keywords

Search

Navigation